Adding to the pressure is that CVS Health has retained coverage of Zepbound's arch rival Wegovy (semaglutide), sold by Novo ...

Novo Nordisk shares rose by more than 5% after the Danish weight-loss drug maker said the Food and Drug Administration accepted a new drug application for a pill form of its popular Wegovy injection.

In a nutshell People with cardiovascular conditions have hearts that function nearly 5 years older than their actual age, ...

Study participants were randomly assigned 2:1 to receive oral semaglutide 25mg (n=205) or placebo (n=102), as an adjunct to lifestyle intervention. The coprimary endpoints were the relative change in ...

Novo Nordisk said the Food and Drug Administration accepted its submission of a new drug application for a Wegovy pill to treat obesity amid a tense race to get an oral weight-loss medication on the ...

A decision is expected in the fourth quarter of 2025.

Researchers have developed a revolutionary new way to find out the 'true age' of your heart using MRI. A new study shows how an MRI scan can reveal your heart's functional age -- and how unhealthy ...

When you go in for a wellness exam, oftentimes the first things the medical assistant does is take your height and weight.

Eli Lilly's Zepbound loses CVS coverage to Wegovy, prompting analyst debate on pricing pressures and long-term obesity market ...

The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

UNAM's Applied Literature Seminar is blending literature and real-world transformation to tackle Mexico's biggest social ...